News

Under the agreement, LigoCyte will receive milestone payments on the successful development of drug candidates. The collaboration includes an opportunity for co-development, co-promotion, and sharing of profits resulting

According to the company, Provecta was injected once into one to 20 tumors in each subject. In addition to these treated tumors, an additional one to three tumors

The company expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock in connection with the offering. Goldman, Sachs

Henri Termeer, chairman and CEO said: “The expansion of Allston Landing will help sustain the continued growth of Genzyme’s products. It will enable us to continue to fulfill

Samaritan can now proceed with its proposed Phase II clinical study of Cushing’s syndrome SP-6300’s efficacy in patients experiencing hypercortisolism. Dr Janet Greeson, CEO, said: “We are extremely

In June, StemCells said that the four patents were pending reexamination by the US Patent and Trademark Office (PTO) based on petitions from Neuralstem. StemCells also noted defendants

The candidate, IPI-504, currently being evaluated in two separate multi-center clinical trials in patients with gastrointestinal stromal tumors (GIST) and other soft tissue sarcomas (STS), and in patients

The objective of the trial is to establish the maximum tolerated dose (MTD) and safety profile of Cloretazine (VNP40101M) in combination with Temodar (temozolomide) and then to study

Pursuant to the parties agreement, Sontra has acquired all of the outstanding shares of Echo common stock in exchange for an aggregate of 6.25 million shares of Sontra